Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination

International Journal of Cancer

Volumn 137, Issue 1, 2015, Pages 25-36

  Jannasch, Katharina ^a   Wegwitz, Florian ^a,b   Lenfert, Eva ^b   Maenz, Claudia ^b   Deppert, Wolfgang ^b   Alves, Frauke ^a,c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

breast cancer; chemotherapy; disseminated tumor cells; recurrent tumor growth; transgenic tumor mouse models

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTOCHEMISTRY; HUMIDIFIER; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MINIMAL RESIDUAL DISEASE; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL;

EID: 84930386648     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29369     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Mathiesen RR, Fjelldal R, Liestol K, et al. High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer 2012; 131: E405-15.
3. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
4. Janni W, Vogl FD, Wiedswang G, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse-a European pooled analysis. Clin Cancer Res 2011; 17: 2967-76.
5. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
6. Fantozzi A, Christofori G,. Mouse models of breast cancer metastasis. Breast Cancer Res 2006; 8: 212.
7. Shultz LD, Ishikawa F, Greiner DL,. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-30.
8. Schulze-Garg C, Lohler J, Gocht A, et al. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000; 19: 1028-37.
9. Heinlein C, Krepulat F, Lohler J, et al. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 2008; 122: 1701-9.
10. Jannasch K, Dullin C, Heinlein C, et al. Detection of different tumor growth kinetics in single transgenic mice with oncogene-induced mammary carcinomas by flat-panel volume computed tomography. Int J Cancer 2009; 125: 62-70.
11. Otto B, Gruner K, Heinlein C, et al. Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression. Int J Cancer 2013; 132: 1300-10.
12. Otto B, Streichert T, Wegwitz F, et al. Transcription factors link mouse WAP-T mammary tumors with human breast cancer. Int J Cancer 2013; 132: 1311-22.
13. Krepulat F, Lohler J, Heinlein C, et al. Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice. Oncogene 2005; 24: 4645-59.
14. Wegwitz F, Kluth MA, Manz C, et al. Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system. PLoS One 2010; 5: e12103.
15. Levine MN, Pritchard KI, Bramwell VH, et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23: 5166-70.
16. Shrivastav S, Stone KR, Paulson DF, et al. Activation of cyclophosphamide for in vitro testing of cell sensitivity. Cancer Res 1980; 40: 4443-5.
17. Lenfert E, Maenz C, Heinlein C, et al. Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice. Int J Cancer 2014; doi: 10.1002/ijc.29186.
18. Provenzano PP, Eliceiri KW, Campbell JM, et al. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006; 4: 38.
19. Provenzano PP, Inman DR, Eliceiri KW, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008; 6: 11.
20. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
21. Tam WL, Weinberg RA,. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013; 19: 1438-49.
22. Rottenberg S, Nygren AO, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007; 104: 12117-22.
23. Chang JC, Wooten EC, Tsimelzon A, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005; 23: 1169-77.
24. Idowu MO, Kmieciak M, Dumur C, et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43: 364-73.
25. Martin TA, Jiang WG,. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. Oncol Rep 2014; 31: 262-72.
26. Taube JH, Herschkowitz JI, Komurov K, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010; 107: 15449-54.
27. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
28. Gupta PB, Chaffer CL, Weinberg RA,. Cancer stem cells: mirage or reality? Nat Med 2009; 15: 1010-2.
29. Hartkopf AD, Taran FA, Wallwiener M, et al. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy. Breast Cancer Res 2013; 15: R94.
30. Mestas J, Hughes CC,. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731-8.